Imaging, Diagnosis, Prognosis Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas

Purpose: We examined the frequency, tumor characteristics, and prognostic impact of HER2 protein expression and gene amplification in patients with curatively resected esophageal adenocarcinoma (EAC). Experimental Design:HER2 expression was analyzed by immunohistochemistry (IHC) in surgical EAC specimens (n 1⁄4 713). Gene amplification was examined by FISH in a large subset (n 1⁄4 344). Most tumors were T3–4 (66%) or node positive (72%); 95%were located in the esophagus or gastroesophageal junction. No patient received neoadjuvant therapy. Cox models were used. Results:Overall, 17%of EACswereHER2positive (i.e., IHC3þor IHC2þwith amplification),with strong agreement betweenHER2 amplification (HER2/CEP17 ratio 2) and expression (k1⁄40.83).HER2positivity was significantly associated with lower tumor grade, less invasiveness, fewer malignant nodes, and the presence of adjacent Barrett’s esophagus (BE). EACs with BE had higher odds of HER2 positivity than EACs without BE, independent of pathologic features [OR1⁄4 1.8 (95% CI: 1.1–2.8), P1⁄4 0.014]. Among all cases, HER2 positivity was significantly associatedwith disease-specific survival (DSS) in amanner that differed by the presence or absence of BE (Pinteraction 1⁄4 0.0047). In EACs with BE, HER2 positivity was significantly associated with improved DSS [HR 1⁄4 0.54 (95% CI: 0.35–0.84), P 1⁄4 0.0065] and overall survival (P 1⁄4 0.0022) independent of pathologic features, but was not prognostic among EACs without BE. Conclusions: HER2 positivity was shown in 17% of resected EACs and associated with reduced tumor aggressiveness. EACs with BE had nearly twice the odds of being HER2 positive and, within this subgroup, HER2 positivity was independently associated with improved survival. Clin Cancer Res; 18(2); 546–54.